Regeneron was in the news in 2020 because of its antibody-drug that was found to be a useful treatment for COVID. However, the company is more than just an antibody specialist. It has a portfolio of products in oncology, ophthalmology, arthritis, asthma, and other areas. Biotech stocks with a strong track record of product development and innovation have shown the ability to compete effectively in the past. Such products with patent protection can potentially earn the company billions of dollars over a longer period. If you are looking to buy today’s biotech stock, then companies like Regeneron could be worth analyzing further. An interesting fact about Regeneron is that it was founded by physician-scientists more than three decades ago. The company has followed a science-driven approach to successfully bring to the market nine FDA-approved drugs.
Regeneron’s Product Pipeline And Prospects
Regeneron is known to have more than 30 products in the pipeline for approval. One drug that has recently been in the news is Dupixent. It is meant to treat moderate-to-severe atopic dermatitis in younger children between the ages of 6 months to 5 years. Dupixent showed positive results in Phase 3 trials and has been developed in partnership with French pharma company Sanofi. Dupixent is being projected by analysts to be potentially among the top-selling drugs in the world by the year 2030. Worldwide sales for Dupixent rose by 59% year-over-year when comparing Q22021 with Q22020. If you are an investor who is looking to buy now biotech stock, then the prospects of Dupixent and its future performance are pieces of information worth tracking.
Regeneron’s stock had gone below $300 back in September 2020. Since then, it rallied to cross $600 by July 2020. Regeneron was trending up during the March 2020 market crash when many other stocks were falling across sectors. The stock was last trading at $675.75 as of 2nd September 2021.